Eli Lilly and Company (NYSE:LLY) Shares Up 1.1% - Still a Buy?

Key Points

• Eli Lilly's stock increased by 1.1% to $820.97, though trading volume was down 35% compared to its average.
• Brokerage ratings vary: BMO Capital Markets set a new price target of $930.00, while Daiwa Capital Markets downgraded the stock to "neutral" with a $700.00 target.
• The company reported strong earnings of $6.31 per share for the last quarter, surpassing analysts' expectations and showcasing a 37.6% revenue increase year-over-year.

Eli Lilly and Company (NYSE:LLY - Get Free Report) traded up 1.1% on Thursday . The stock traded as high as $824.70 and last traded at $820.97. 2,626,366 shares were traded during mid-day trading, a decline of 35% from the average session volume of 4,026,686 shares. The stock had previously closed at $812.43.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on LLY. BMO Capital Markets raised their price target on Eli Lilly and Company from $840.00 to $930.00 and gave the company an "outperform" rating in a report on Monday. HSBC raised their price target on Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. Daiwa Capital Markets cut Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 target price for the company. in a research note on Sunday, August 17th. Berenberg Bank reaffirmed a "hold" rating and set a $830.00 target price (down previously from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. Finally, Guggenheim reaffirmed a "buy" rating and set a $948.00 target price on shares of Eli Lilly and Company in a research note on Thursday, October 16th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company's stock. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of "Moderate Buy" and an average target price of $938.61.

Eli Lilly and Company Trading Up 1.1%

The company has a market capitalization of $777.02 billion, a P/E ratio of 53.66, a P/E/G ratio of 1.14 and a beta of 0.47. The company has a 50-day simple moving average of $762.81 and a 200 day simple moving average of $766.75. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter last year, the firm earned $3.92 EPS. Eli Lilly and Company's revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Insider Activity at Eli Lilly and Company

In related news, CEO David A. Ricks purchased 1,632 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the purchase, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director J Erik Fyrwald purchased 1,565 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the purchase, the director owned 74,578 shares in the company, valued at $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 4,514 shares of company stock worth $2,894,841 in the last three months. Company insiders own 0.13% of the company's stock.

Institutional Trading of Eli Lilly and Company

Institutional investors have recently bought and sold shares of the stock. Precedent Wealth Partners LLC boosted its stake in Eli Lilly and Company by 15.3% in the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company's stock valued at $229,000 after buying an additional 39 shares in the last quarter. Capital Advisors Inc. OK boosted its stake in Eli Lilly and Company by 6.8% in the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company's stock valued at $5,260,000 after buying an additional 429 shares in the last quarter. Family CFO Inc acquired a new stake in Eli Lilly and Company in the 2nd quarter valued at $54,000. Duquesne Family Office LLC boosted its stake in Eli Lilly and Company by 52.5% in the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock valued at $78,321,000 after buying an additional 32,640 shares in the last quarter. Finally, Corient IA LLC acquired a new position in Eli Lilly and Company in the first quarter worth $570,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.